<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177123</url>
  </required_header>
  <id_info>
    <org_study_id>INN-007</org_study_id>
    <nct_id>NCT02177123</nct_id>
  </id_info>
  <brief_title>Post Market Study of the InnFocus MicroShunt</brief_title>
  <official_title>Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect additional safety and effectiveness data on the
      InnFocus MicroShunt (MIDI Arrow) in subjects suffering from primary open angle glaucoma who
      are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥
      18 mm Hg and ≤ 35 mm Hg and/or where glaucoma progression warrants surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2014</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure reduction</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Reduction in intraocular pressure relative to the pre-operative value will be assessed at each post-operative visit (Day 1, Day 7, Week 4, Month 3, 6, 9, 12, and 24) with a first measurement of success at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glaucoma medication usage</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Level of glaucoma supplemental medical therapy at Month 12 and 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 24 months follow-up</time_frame>
    <description>Incidence of all device and/or procedure-related Adverse Events during the study.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>InnFocus MicroShunt Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InnFocus MicroShunt implantation in a primary open angle glaucoma subject using an ab externo subconjunctival/subTenons access with direct connection to the anterior chamber of the eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InnFocus MicroShunt implantation</intervention_name>
    <description>Implantation will include the use of Mitomycin C applied with sponges.</description>
    <arm_group_label>InnFocus MicroShunt Surgery</arm_group_label>
    <other_name>InnFocus MicroShunt</other_name>
    <other_name>MIDI Arrow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has mild to moderate primary open glaucoma where the intraocular pressure is
             not adequately controlled on maximum tolerated medical therapy and has intraocular
             pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on
             glaucoma medications and/or where glaucoma progression warrants surgery.

          2. Primary open angle glaucoma diagnosis based on glaucomatous optic nerve damage as
             evidenced by any of the following optic disc or retinal nerve fiber layer structural
             abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos:

               1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially
                  at the inferior or superior poles.

               2. Localized abnormalities of the peripapillary retinal nerve fiber layer,
                  especially at the inferior or superior poles.

               3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural
                  tissue.

               4. Disc rim or peripapillary retinal nerve fiber layer hemorrhages.

        Exclusion Criteria:

          1. Active iris neovascularization, active proliferative retinopathy or other ophthalmic
             disease that could confound study results.

          2. Iridocorneal endothelial syndrome.

          3. Epithelial or fibrous downgrowth.

          4. Secondary glaucoma such as post-trauma, pseudo-exfoliative, etc.

          5. Chronic ocular inflammatory disease.

          6. Prior argon laser, selective laser, or micropulse trabeculoplasty within 90 days of
             enrollment.

          7. Inability to obtain accurate IOP measurement throughout the study. For example: a
             history of corneal surgery, corneal opacities or disease/pathology (Active corneal
             infection or Fuchs dystrophy are examples.).

          8. Severe anterior or posterior blepharitis.

          9. Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal
             phacoemulsification (cataract) surgery at least 6 months prior to enrollment.

         10. Prior laser peripheral iridotomy.

         11. Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)

         12. Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy
             and classified as Shaffer Grade 0 or 1.

         13. Previous cyclodestructive procedure.

         14. Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Van de Weyer, Optometrist</last_name>
    <role>Study Director</role>
    <affiliation>InnFocus Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Ophtalmologique Universitaire de Grenoble, Hôpital A. Michallon - CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint-Joseph, Service d'Ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Ophtalmologique de la Clinique Mutualiste</name>
      <address>
        <city>Pessac</city>
        <zip>33608</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicovision - Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève, Policlinique d'Ophtalmologie</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma shunt</keyword>
  <keyword>glaucoma drainage device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

